DERM - Dermira, Inc.
| Previous Close | 11.67 |
| Open | 11.88 |
| Bid | 12.40 x 1000 |
| Ask | 0.00 x 1100 |
| Day's Range | 11.19 - 13.31 |
| 52 Week Range | 5.25 - 15.48 |
| Volume | 3923390 |
| Avg. Volume | 1,360,609 |
| Market Cap | 702M |
| Beta (5Y Monthly) | 1.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.37 |
| Earnings Date | Nov 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.67 |
- Business Wire
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Business Wire
Dermira Receives Fast Track Designation from FDA for Lebrikizumab for the Treatment of Atopic Dermatitis
Dermira Receives Fast Track Designation from FDA for Lebrikizumab for the Treatment of Atopic Dermatitis
- Simply Wall St.
Is Dermira (NASDAQ:DERM) Using Debt In A Risky Way?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
- Insider Monkey
Here’s What Hedge Funds Think About Dermira Inc (DERM)
Is Dermira Inc (NASDAQ:DERM) a good bet right now? We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of […]
- Business Wire
Dermira to Participate in December Investor Conferences
Dermira, Inc. , a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will participate in two investor conferences in December.
- Business Wire
Dermira Presents New Scientific Research Findings from the Lebrikizumab Program at Leading International Itch Conference
Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that new scientific findings highlighting the role of interleukin-13 (IL-13) in amplifying itch and the role lebrikizumab plays in reducing itch, will be presented at the 10th World Congress on Itch taking place November 17-19 in Sydney, Australia.
- Business Wire
Dermira Elects Halley E. Gilbert to its Board of Directors
Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced the election of Halley E. Gilbert to its board of directors. “We are excited to welcome Halley Gilbert to Dermira’s board of directors,” said Tom Wiggans, chairman and chief executive officer of Dermira.
- Business Wire
Dermira to Participate in the Guggenheim Healthcare Talks Idea Forum, Neuro/Immunology Day
Dermira, Inc. , a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will participate in a fireside chat at the Guggenheim Healthcare Talks Idea Forum, Neuro/Immunology Day on Monday, November 18, 2019 at 9:00 a.m....
- Thomson Reuters StreetEvents
Edited Transcript of DERM earnings conference call or presentation 5-Nov-19 9:30pm GMT
Q3 2019 Dermira Inc Earnings Call
- Zacks
The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co
The Zacks Analyst Blog Highlights: LHC, Retrophin, Dermira and Merck & Co
- Zacks
Pharma Sector Tops in October: Best ETFs & Stocks
Pharma sector wins in October, making these ETFs and stocks winners.
- Zacks
Trade Deal Delay Unlikely to Hit U.S. Healthcare: 4 Picks
The healthcare sector seems to be least affected by a protracted U.S.-China trade war. Stellar third-quarter earnings make the sector a hotbed for money.
- TipRanks
3 Biotech Stocks Needham Expects to Double in the Next 12 Months
Overall, the stock markets have been gaining in recent months. October saw a 2% bump for the general S&P 500 index, as did the Dow Jones average. But not all market segments are created equal, and some brought stronger returns for investors than others. The biotech industry, for example, had a particularly good month in the stock markets.The Biotech ETF, a sub-index of the NASDAQ that tracks the performance of stocks in the biotechnology and pharmaceutical sectors, rose 8% last month, four times the broader market’s average. The gains were led by the big names in the sector, but smaller stocks were also showing strength. Analysts from Needham, one of Wall Street’s top financial research firms, have picked out three small-cap biotechs that are showing a combination of recent gains and fantastic upside.Akcea Therapeutics (AKCA)A publicly traded company since July 2017, Akcea focuses on treatments for rare, serious diseases. The company’s main approved product, Tegsedi, treats “polyneuropathy caused by hereditary transthyretin-mediated amyloidosis” in adults. The drug is available in the US, Canada, and the EU. Waylivra, for the treatment of familial chylomicronemia syndrome, has been approved in the EU.Akcea has an active research pipeline with new drugs in all stages of testing, from pre-clinical to up to the FDA registration process. Most of Akcea’s products are for the treatment of cardiometabolic lipid disorders.In the Q3 earnings report, Akcea beat the EPS forecast by 38%, showing a net loss of 34 cents per share against the forecast 55 cents. In addition to beating the estimate, the quarterly EPS also showed a strong improvement from the year-ago quarterly loss of 58 cents. During the month of October, AKCA gained 24%, triple the overall biotech sector gains.Needham’s 4-star analyst Chad Messer writes of AKCA shares, “AKCA shares could go higher if the company can establish a pathway to approval for Waylivra with the FDA in FCS, if Waylivra reports positive data in FPL, or AKCEA-APOCIII-LRx, AKCEA-APO(a)-LRx, or AKECA-ANGPTL3-LRx report positive Phase II data. AKCA shares could also be driven higher by higher than expected sales for Tegsedi in FAP-ATTR.” Messer gives AKCA stock a $45 price target, implying a 127% upside and reflecting his optimism on the company’s path forward in the regulatory processes.With 3 recent Buy ratings, and only 1 Hold, AKCA has a Strong Buy from the analyst consensus. Shares sell for a modest $19.53, and the $40.50 average price target suggests an upside potential of 104%. (See Akcea stock analysis on TipRanks) Dermira (DERM)As its name suggests, Dermira is a pharmaceutical company focusing on dermatalogical issues, that is, on the treatment of chronic skin conditions. It’s easy to overlook, but the skin is the largest organ of the human body, and fills a wide range of rolls from keeping our insides in while keeping the outside out, to helping us regulate our body temperature.Dermira’s first approved products, Qbrexza, is a medicated cloth designed to treat hyperhidrosis – extreme sweating – in the armpits. The company also has Lebrikizumab, a treatment for atopic dermatitis, has just entered Phase 3 testing. Other projects are still in the pre-clinical testing phases.Like AKCA above, Dermira showed a strong Q3 despite operating at a net loss. The net loss per earning was $1.06, a 24% improvement from the expected EPS loss of $1.40. This marked the third time in the past year that DERM has beating the earnings forecast. The positive earnings news came after the stock had gained 15% in October.In a November 6 report on DERM, Needham analyst Serge Belanger focused on the company’s two main pharmaceutical products. He wrote, “The bulk of the recent DERM news flow revolved around lebrikizumab and its ph 3 program that got underway in mid-Oct. The 3Q19 financials and update mostly centered around the launch progression of Qbrexza, which generated sales of $10.2MM, surpassing Street expectations… Qbrexza is on pace to meet the low-$30MM 2019 sales guidance.”Belanger maintained his firm’s Buy rating on this stock, and gave it a $20 price target. His target implies a 185% potential to the upside.DERM gets a Strong Buy analyst consensus rating, with 3 Buys set in just the past week. The stock is a bargain price, at $7, but the potential of its new drugs and its research pipeline give it a high average price target of $19, and an impressively robust upside potential of 171%. (See Dermira stock analysis on TipRanks) G1 Therapeutics (GTHX)Once an almost certainly deadly, new treatments in recent years have brought hope to many cancer patients. G1 has a series of drugs in testing for small cell lung cancer, breast cancer, and colorectal cancer. The lung cancer treatments are in late stage testing and scheduled for regulatory submission in 2020. Also in 2020, the breast cancer and colorectal cancer treatments are scheduled to start trials.G1 shares were mostly flat in October, reflecting the differences between this company and the two listed above: where its peers above showed strong positive surprises in Q3 earnings, G1’s EPS loss was in line with estimates at 86 cents. Without any strong earnings surprise, and without any products post-approval, G1 did not shake up the expectations.Where this stock shines, however, is in long-term performance and forward potential. GTHX is up 20% year-to-date, a reflection of the hopes pinned on the latent possibilities of new cancer treatments. Chad Messer, quoted above, touches on this in his report on GTHX when he writes, “G1 remains on track to file a trilaciclib NDA and MAA in 2020 for myelopreservation in small cell lung cancer (SCLC). The next driver for GTHX is updated results from the Phase Ib study of lerociclib…” Messer’s price target of $74 suggests an upside of 223% to the stock – significantly higher than that implied for the stocks above.Messer is not the only analyst impressed by GTHX’s prospects in the cancer treatment research field. The stock has Buy ratings from 6 analysts recently, making its consensus rating a unanimous Strong Buy. Shares are trading for $22.82, and the average stock-price forecast of $65.50 indicates an upside potential of 169%. (See GTHX stock analysis on TipRanks)
- Zacks
Jazz Pharma (JAZZ) Q3 Earnings Beat, Xyrem Drives Sales
Jazz Pharmaceuticals (JAZZ) beats third-quarter 2019 earnings and revenue estimates and raises its guidance for 2019.
- Zacks
Dermira (DERM) Reports Q3 Loss, Tops Revenue Estimates
Dermira (DERM) delivered earnings and revenue surprises of 24.29% and 4.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Dermira Reports Third Quarter 2019 Financial Results and Provides Corporate Update
- QBREXZA® cloth net product sales of $10.2M
- Business Wire
Dermira to Report Third Quarter 2019 Results and Host Conference Call on Tuesday, November 5, 2019
Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, will report financial results for the quarter ended September 30, 2019 and provide an operational update after market close on Tuesday, November 5, 2019. Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions.
- Simply Wall St.
Did You Manage To Avoid Dermira's (NASDAQ:DERM) Devastating 79% Share Price Drop?
As every investor would know, not every swing hits the sweet spot. But really bad investments should be rare. So spare...
- American City Business Journals
These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year
While initial public offerings get most of the splash, public companies also are raking in cash with follow-on offerings. How long will the Wall Street spigot stay open?
- Business Wire
Dermira Presents Data From Phase 2b Study of Lebrikizumab in Patients With Atopic Dermatitis at Fall Clinical Dermatology Conference
- Lebrikizumab demonstrated dose-dependent improvements across endpoints spanning the range of atopic dermatitis signs and symptoms, including skin lesions and pruritus, when administered once every two or four weeks - Improvement in pruritus was reported as early as second day of treatment - Consistent with prior experience, lebrikizumab was well-tolerated, with low rates of conjunctivitis - Conference ...
- Zacks
Aclaris Divests Rhofade to EPI Health for $55M, Shares Up
Aclaris (ACRS) divests worldwide rights to its rosacea drug, Rhofade, to privately-held EPI Health as part of its restructuring program.
- Zacks
Dermira Starts Lebrikizumab Dosing in Late-Stage Eczema Study
Dermira (DERM) starts a phase III program for evaluation of its monoclonal antibody candidate, lebrikizumab, in adolescents and adult patients with atopic dermatitis, the most common form of eczema.
- Business Wire
Dermira to Present Data from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis at Fall Clinical Dermatology Conference
Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that detailed primary results of its Phase 2b study of lebrikizumab in patients with moderate-to-severe atopic dermatitis will be reported at the 39th Annual Fall Clinical Dermatology Conference in Las Vegas, NV, October 17-20, 2019. In addition, the company will host a conference call and webcast on October 17, 2019, during which Dr. April W. Armstrong will discuss the data presented and company management will provide an overview of the lebrikizumab Phase 3 clinical development program.
